ArticleBMC immunology2025
Expression and clinical significance of plasma microRNA-155 in patients with primary Sjögren's disease.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the expression profile and clinical relevance of microRNA-155 (miRNA-155) in patients with primary Sjögren’s disease (pSD).
methodsWe enrolled 75 pSD patients, categorized into untreated (n = 41) and treated (n = 34) subgroups, along with 40 healthy controls. Plasma miRNA-155 levels were quantified using quantitative real-time PCR (qRT-PCR) in a subset of participants (24 pSD patients, 10 controls). Clinical and immunological parameters, including erythrocyte sedimentation rate (ESR), anti-SSB antibodies, and organ involvement, were analyzed for correlations with miRNA-155 expression.
resultsmiRNA-155 expression was significantly downregulated in pSD patients compared to controls (P = 0.001). Treated patients had significantly higher miRNA-155 levels than untreated patients (P = 0.045), although both were lower than controls. Subgroup analyses revealed elevated miRNA-155 levels in patients with higher ESR (P = 0.045), anti-SSB seropositivity (P = 0.001), and Chisholm grade III labial gland pathology (vs. grade IV, P = 0.049). Conversely, patients with interstitial lung disease exhibited reduced miRNA-155 expression (P = 0.007). Positive correlations were observed between miRNA-155 and ESR (r = 0.630, P = 0.001) and IgA levels (r = 0.542, P = 0.009). An exploratory analysis suggested lower baseline miRNA-155 levels may be associated with a greater therapeutic reduction in ESR.
conclusionspSD patients demonstrate significantly decreased plasma miRNA-155 expression. These levels are associated with treatment status, anti-SSB antibody production, pulmonary involvement, and labial gland pathology. miRNA-155 levels are also correlated with systemic inflammation and IgA dysregulation, suggesting its potential as a complex biomarker in pSD pathogenesis and for monitoring disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.